reason report
solid april test volum y/i chang
 ahead alreadi reduc estim
though suggest first week april compani
seen volum declin genom test includ
revenu expect test product
revenu compar prior also announc
seri cost cut initi includ execut board pay
reduct furlough employe mostli sale hire
freez expect help off-set ensu
driven headwind us remain attract diagnost stori
three classifi test reduc diagnost uncertainti patient
grow biopharma presenc strong pipelin assay
earlier acquisit ncounter platform reiter op rate
pt move lower sale
revenu ahead expect covid impact start
weigh cost reduct prudent recal recent updat
model reflect modest impact last two week
march howev strong perform first month quarter
help mitig headwind first day april see
y/i volum declin pull estim even
expect even larger volum impact second quarter
like remain rang least april gradual
recoveri rest quarter reach model y/
declin quarter despit signific headwind expect
encourag hear clia lab continu run
compani undergo cost cut measur though remain cautiou
may take time custom patient return
cut cost mitig covid impact announc
number cost cut measur includ reduct ceo
bonni anderson base pay target bonu addit pay cut
board director execut employe
return normal oper also announc furlough
employe temporari hire freez effort secur vendor discount
halt nonessenti outsid spend anticip
measur provid mitig expect declin
revenu believ time busi rebound build
lead thyroid grow lung cancer diagnost posit
updat model reflect quarter volum commentari
ultim expect volum revenu impact significantli
second quarter reduc revenu estim
full year estim drop
recoveri drag
compani inform svb leerink llc research
revenu million
life scienc tool diagnost
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
address company-estim diagnost market current commerci
product pipelin product help reduc ambigu diagnosi sizabl
subset thyroid lung cancer patient dramat reduc unnecessari surgeri
develop proprietari express test afirma identifi benign thyroid
nodul indetermin tradit cytolog help physician patient confid
forgo unnecessari thyroid surgeri afirma believ path becom standard
care given thyroid fna fine needl aspir found
indetermin year suitabl test afirma alreadi driven near
penetr market compani expect reach longer term
company-estim market eu market
veracyt second test percepta bronchial gene express classifi
neg predict valu help identifi patient consid low risk initi
bronchoscopi result found inconclus help reduc unnecessari surgeri
save overal cost system percepta bronchial classifi address
bronchoscopi everi year lung nodul reveal ct inconclus
case drive market opportun percepta test annual
market reimburs medicar continu garner commerci payer
also commerci envisia third test neg classifi test idiopath
pulmonari fibrosi ipf drive total address market three diagnost test
believ reimburs continu import driver revenu
beyond test volum compani continu build stronger payer base time
gain increasingli cover contract live drive adopt test
vcyt multi-year collabor innov earli stage discoveri therapeut arm
 js global lung cancer initi develop non-invas nasal swab diagnost
test call nasarisk lung cancer valid potenti field injuri approach
part collabor receiv payment addit
follow futur clinic studi grow reveal data non-invas nasal swab
assay octob show test risk classifi patient suspici
lung nodul manag estim market opportun eu
combin opportun compani plan begin make test avail
earli nasarisk product launch hope develop futur
nasal test earli detect lung cancer pre-ct scan order pursu larg earli
screen market repres global compos us eu
rest world
decemb announc definit agreement nanostr exclus
licens ncounter platform diagnost use transact grant access
intern market reduc cost structur expand menu diagnost assay
also acquir prosigna test in-develop lymphmark assay expand
oncolog indic part transact togeth deal expand vcyt global
market opportun expect us busi remain uninterrupt
continu oper usual util ncounter platform lower cog begin
recogn larg global opportun
share current trade ev/sal compar diagnost
peer qtnt gh multipl averag
given higher rate reimburs afirma becom standard care market
newli launch test includ percepta envisia gain traction next year
back strong clinic data biopharma revenu ramp addit potenti
prosigna lymphmark assay believ share could trade premium peer
realiz least ev/sal estim result pt
primari risk price target includ limit reimburs
rate decis move forward visibl test includ percepta envisia fda
regul financ commit given neg cash flow near term
declin reimburs could sever impact revenu major risk
reimburs rate could decreas dramat current reimburs rate
among highest industri much revenu base
reimburs rate impact amount test administ adopt rate
exist new test vcyt ramp would sever impact refil reject
even wors reimburs rate continu fall given still early-stag compani
visibl still somewhat limit despit encourag sign still early-stag
compani neg net incom provid progress report afirma
encourag result test gain traction howev still plenti uncertainti
busi given model still show neg earn least busi
develop forecast expect face challeng new compani face
competit disadvantag limit visibl
fda regul remain risk regulatori concern fda decis
impact product still earli stage ramp envisia
could impact fda given nascent natur test fda regul could impact
product number product offer compani increas regul
fda would requir addit sg expens satisfi complianc increas cost
could also affect abil ramp
addit financ could still happen posit cash flow come later expect
possibl may need addit financ given expect neg net incom
near term expect posit cash flow come later expect compani
need anoth round financ exist debt could lead addit interest expens
increas net debt balanc sheet could also lead increas capit cost
recogn potenti impact oncolog diagnost market result
on-going impact outbreak extend beyond current expect would
like headwind oncolog diagnost compani result fewer patient visit
servic
interest expens incom net
sg sale
 sale
oper expens sale
compani report svb leerink estim
